Ampio Prescription drugs, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update Call

ENGLEWOOD, Colo., March 23, 2022 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical organization concentrated on the advancement of immunomodulatory therapies for the procedure of agony ensuing from osteoarthritis, declared that the Organization will be hosting its fourth quarter earnings and business enterprise update call March 29 at 4:30pm EST.

Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.)

Ampio Prescribed drugs Logo. (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.)

Convention Connect with Information

Date/Time: March 29, 2022, at 4:30 pm EST
Conferencing Link:
Access Code: 66744

Canada dial-in selection (Toll Free):

1 833 950 0062

Canada dial-in selection (Local):

1 226 828 7575

US dial-in selection (Toll Free of charge):

1 844 200 6205

US dial-in number (Local):

1 646 904 5544

Access code:


*Participants will have to have to enter the participant entry code in advance of becoming met by an operator

In purchase to submit queries, individuals need to have World wide web connectivity, as thoughts will only be addressed by means of the webcast. The meeting connect with line will be in pay attention-only manner.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a biopharmaceutical firm generally focused on the development of immunology-primarily based therapies for the treatment method of discomfort ensuing from osteoarthritis. Ampio’s lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual home defense extending through 2037 and may well be qualified for 12-year Food and drug administration current market exclusivity upon approval as a novel biologic beneath the Biologics Rate Competitors and Innovation Act (BPCIA).

Forward Searching Statements

Ampio’s statements in this push release and the webinar that are not historic truth, and that relate to potential designs or situations, are forward-seeking statements inside the meaning of the Personal Securities Litigation Reform Act of 1995. Forward-on the lookout statements can be determined by the use of words these types of as “believe that,” “anticipate,” “program,” “foresee,” and very similar expressions. These forward-on the lookout statements contain statements concerning Ampio’s expectations with respect to Ampion and its classification, as effectively as those people linked with regulatory approvals and other Fda decisions, the Organic License Software (BLA), the capacity of Ampio to enter into partnering preparations, scientific trials and selections and variations in enterprise ailments and comparable gatherings, the ability to receive regulatory acceptance to conduct medical trials, that Ampion may well be made use of to address ARDS induced by COVID-19, all of which are inherently subject matter to various threats and uncertainties. The dangers and uncertainties associated incorporate those detailed from time to time in Ampio’s filings with the Securities and Trade Fee, including with no limitation, beneath Ampio’s Yearly Report on Sort 10-K and other paperwork filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these ahead-on the lookout statements, regardless of whether as a consequence of new data, long term activities or in any other case.

Trader and Media Contacts:
Tony Russo or Nic Johnson
Russo Associates
[email protected]
[email protected]



Look at first articles to down load multimedia: drugs-inc-to-keep-fourth-quarter-2021-earnings-and-company-update-call-301508715.html

Supply Ampio Prescribed drugs, Inc.